A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people with Parkinson’s disease with or without a GBA1 mutation. We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - |
| Net Income | -19M | -22M | -18M | -14M | -3.6M |
| EPS | $-0.61 | $-1.71 | $-1.48 | $-1.37 | $-1.33 |
| Free Cash Flow | 0 | -19M | -15M | -12M | -3.3M |
| ROIC | -126.6% | -94.5% | -90.8% | -39.2% | -51.7% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.07 | 0.05 | 0.03 | 0.02 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -18M | -22M | -18M | -14M | -3.5M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -328.1% | -177.0% | -93.2% | -39.9% | -57.7% |
| Shares Outstanding | 36M | 13M | 12M | 10M | 12M |
| Metric | 2020 | 2021 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -3.5M | -14M | -18M | -22M | -18M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -3.6M | -14M | -18M | -22M | -19M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -51.7% | -39.2% | -90.8% | -94.5% | -126.6% |
| ROE | -57.7% | -39.9% | -93.2% | -177.0% | -328.1% |
| ROA | -37.3% | -35.6% | -73.0% | -119.7% | -176.7% |
| Cash Flow | |||||
| Op. Cash Flow | -3.2M | -12M | -15M | -19M | -17M |
| Free Cash Flow | -3.3M | -12M | -15M | -19M | 0 |
| Owner Earnings | -3.3M | -13M | -16M | -22M | -21M |
| CapEx | 21K | 94K | 119K | 15K | 0 |
| Maint. CapEx | 10K | 15K | 64K | 84K | 84K |
| Growth CapEx | 11K | 79K | 55K | 0 | 0 |
| D&A | 10K | 15K | 64K | 84K | 84K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 82K | 839K | 1.5M | 3.3M | 3.3M |
| Debt Repayment | 0 | 22K | 79K | 89K | 89K |
| Balance Sheet | |||||
| Net Debt | -6.8M | -36M | -20M | -16M | -8.4M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 8.8M |
| Long-Term Debt | 716K | 590K | 495K | 449K | 449K |
| Debt/Equity | 0.12 | 0.02 | 0.03 | 0.05 | 0.07 |
| Interest Coverage | N/A | N/A | N/A | -45.0 | -45.0 |
| Equity | 6.2M | 35M | 19M | 13M | 5.9M |
| Total Assets | 9.6M | 39M | 24M | 19M | 11M |
| Total Liabilities | 3.4M | 4.2M | 5.2M | 6.0M | 5.1M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -3.5M | -7.0M | -21M | -39M | -39M |
| Working Capital | 6.9M | 35M | 17M | 13M | 13M |
| Current Assets | 9.0M | 38M | 21M | 18M | 18M |
| Current Liabilities | 2.1M | 2.6M | 4.1M | 4.9M | 4.9M |
| Per Share Data | |||||
| EPS | -1.33 | -1.37 | -1.48 | -1.71 | -0.61 |
| Owner EPS | -0.28 | -1.30 | -1.37 | -1.71 | -0.57 |
| Book Value | 0.52 | 3.43 | 1.59 | 0.97 | 0.16 |
| Cash Flow/Share | -0.27 | -1.22 | -1.24 | -1.45 | -0.53 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 11.9M | 10.1M | 11.9M | 13.0M | 36.1M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -3.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.6 | 1.8 | 3.0 | 11.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -22.8% | -43.1% | -49.3% | N/A |
| Market Cap | N/A | 55M | 34M | 38M | 68M |
| Avg. Price | N/A | 9.09 | 3.66 | 3.87 | 1.87 |
| Year-End Price | N/A | 5.40 | 2.89 | 2.94 | 1.87 |
Gain Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Gain Therapeutics, Inc. (GANX) has a 5-year average return on invested capital (ROIC) of -69.1%. This is below average and may indicate limited pricing power.
Gain Therapeutics, Inc. (GANX) has a market capitalization of $68M. It is classified as a small-cap stock.
Gain Therapeutics, Inc. (GANX) does not currently pay a regular dividend.
Gain Therapeutics, Inc. (GANX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Gain Therapeutics, Inc. (GANX) generated $-19 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Gain Therapeutics, Inc. (GANX) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Gain Therapeutics, Inc. (GANX) reported earnings per share (EPS) of $-1.71 in its most recent fiscal year.
Gain Therapeutics, Inc. (GANX) has a return on equity (ROE) of -177.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Gain Therapeutics, Inc. (GANX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Gain Therapeutics, Inc. (GANX) has a book value per share of $0.97, based on its most recent annual SEC filing.